KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Total Liabilities (2016 - 2025)

Moderna (MRNA) has disclosed Total Liabilities for 9 consecutive years, with -$8.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 366.89% to -$8.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.6 billion, a 366.89% decrease, with the full-year FY2025 number at -$8.6 billion, down 366.89% from a year prior.
  • Total Liabilities was -$8.6 billion for Q4 2025 at Moderna, down from $2.8 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $10.8 billion in Q3 2021 to a low of -$18.9 billion in Q1 2023.
  • A 5-year average of -$2.7 billion and a median of $2.7 billion in 2025 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: skyrocketed 1976.24% in 2021, then crashed 366.89% in 2025.
  • Moderna's Total Liabilities stood at $10.5 billion in 2021, then crashed by 36.0% to $6.7 billion in 2022, then tumbled by 32.12% to $4.6 billion in 2023, then fell by 29.11% to $3.2 billion in 2024, then plummeted by 366.89% to -$8.6 billion in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Total Liabilities are -$8.6 billion (Q4 2025), $2.8 billion (Q3 2025), and -$9.4 billion (Q2 2025).